
Medical Policy



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. When Centers for Medicare and Medicaid (CMS) coverage rules are not fully developed, this medical policy may be used by BCBSM or BCN Medicare Advantage plans 42 CFR § 422.101 (b)(6). Please refer to the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.

***Current Policy Effective Date: 11/1/26**
(See policy history boxes for previous effective dates)

Title: **Diagnosis of Sleep Disorders**

Description

Obstructive sleep apnea (OSA) syndrome is characterized by repetitive episodes of upper airway obstruction due to the collapse of the upper airway during sleep. Polysomnography and portable sleep apnea testing (with sensors for respiratory effort, airflow, and oxygen saturation, or alternatively with peripheral arterial tone [PAT], actigraphy, and oxygen saturation) are established methods for diagnosing OSA. Other proposed methods of diagnosing OSA include limited channel home sleep monitors.

Medical Policy Statement

An unattended sleep study/home sleep apnea test is **established** when criteria are met.

Polysomnography (PSG), an in-laboratory sleep study/sleep apnea test, and a split-night PSG are **established** when criteria are met.

Multiple sleep latency testing (MSLT) and maintenance of wakefulness testing (MWT) for the diagnosis of narcolepsy or idiopathic hypersomnia are **established** when criteria are met.

Noninvasive pulse oximetry as a sole test (as an **alternative** to polysomnography or as a cardiorespiratory study) for diagnosing sleep related breathing disorders OR unattended sleep studies performed with portable equipment with monitoring of three or fewer physiological parameters (type IV devices) are **experimental/investigational**. There is insufficient evidence to determine that the technology results in an improvement in net health outcomes.

Inclusionary and Exclusionary Guidelines

INITIAL UNATTENDED (UNSUPERVISED) HOME SLEEP APNEA TEST (HSAT)

Home sleep apnea studies should be performed with Type II or Type III devices as defined below OR devices using the combination of peripheral arterial tone [PAT], actigraphy, EKG/heart rate, and oxygen saturation.

Inclusions:

Both 1 and 2 must be met:

1. Individuals 18 years of age or older with:
 - a. Observed apneas during sleep; **OR**
 - b. A combination of **at least 2** of the following:
 - Excessive daytime sleepiness evidenced by an Epworth sleepiness >10, inappropriate daytime napping (e.g., during driving, conversation or eating), or sleepiness that interferes with daily activities and is not explained by other conditions;
 - Habitual snoring, defined as occurring every night or most nights per week, or gasping/choking episodes associated with awakenings;
 - Treatment-resistant hypertension (persistent hypertension in an individual taking three or more antihypertensive medications);
 - Obesity, defined as a body mass index (BMI) ≥ 30 kg/m² or neck circumference defined as >17 inches in men or >16 inches in women
Craniofacial or upper airway soft tissue abnormalities, including adenotonsillar hypertrophy, or neuromuscular disease **OR**
 - c. History of stroke (more than 30 days previously), transient ischemic attack, coronary artery disease, or sustained supraventricular tachycardic or bradycardic arrhythmias in patients who meet **ONE** of the criteria listed under “b”(above). **OR**
 - d. **Any** of the following conditions which may suggest OSA when the etiology is unclear:
 - right heart failure,
 - polycythemia,
 - sustained supraventricular or ventricular tachyarrhythmia occurring solely during sleep, **OR**
 - pulmonary hypertension.
2. No exclusions/contraindications to a home sleep apnea test (see below Exclusions/Contraindications to HSAT^a)

REPEAT UNATTENDED (UNSUPERVISED) FOLLOW-UP HOME SLEEP APNEA TEST FOR INDIVIDUALS WITH ESTABLISHED OSA

Inclusions:

A follow-up home sleep apnea study is considered established for an individual with an established diagnosis of OSA and no contraindication to a home sleep apnea study (see below^a) when **ANY** of the following apply:

- On one occasion following:
 - Upper airway surgery performed to treat OSA and/or improve compliance with PAP therapy

- To assess efficacy of current settings of an oral appliance
- To assess efficacy of current settings of a hypoglossal nerve stimulator
- To reevaluate the diagnosis of OSA and need for continued CPAP if there is a significant weight loss (defined as 10% of body weight) since the most recent sleep study
- Prior to implantation of a hypoglossal nerve stimulator (HNS) in a patient who has not had a diagnostic study (home or lab) within the preceding 18 months
- Annual surveillance testing following HNS implantation

^aExclusions/Contraindications To HSAT:

- Individuals younger than 18 years of age
- Moderate or severe chronic pulmonary disease – forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) less than or equal to 0.7 and FEV1 less than 80% of predicted
- Moderate or severe congestive heart failure – New York Heart Association (NYHA) class III or IV
- Congestive heart failure with a history of ventricular fibrillation or sustained ventricular tachycardia in an individual who does not have an implanted defibrillator
- Cognitive or physical impairment that results in inability to apply the home sleep apnea testing equipment when another individual is not available to assist with this task
- Diagnosis suspected or established for ONE of the following conditions:
 - Central sleep disorder
 - Narcolepsy
 - Idiopathic hypersomnia
 - Parasomnias except bruxism and somniloqui (sleep talking)
 - Nocturnal seizures
 - Periodic limb movement disorder (PLMD) when one of the following are present: pregnancy, renal failure, iron deficiency anemia, peripheral neuropathy, use of antidepressant or antipsychotic medications, or continued hypersomnia and clinical symptoms of PLMD after sleep disordered breathing is ruled out by home sleep apnea testing
- Previous technically suboptimal home sleep apnea test in **EITHER** of the following scenarios:
 - A single-night HSAT was technically suboptimal, and the issue is likely to recur if the test is repeated
 - Two nights of study attempted, but the study remains suboptimal after 2 nights
- Previous 1 or 2-night home sleep apnea study did not diagnose OSA in a patient with ongoing clinical suspicion of OSA.
- Oxygen dependence
- History of stroke within the preceding 30 days
- Chronic opioid use when discontinuation is not an option
- Body mass index (BMI) greater than 33 kg/m² and serum bicarbonate level, within the past 1-2 months, is above 28 mmol/L
- Obesity hypoventilation syndrome
 - Established diagnosis of obesity hypoventilation syndrome defined as a body mass index (BMI) greater than 30 kg/m² and hypoventilation which cannot be solely attributed to other conditions such as pulmonary disease, skeletal restriction, neuromuscular weakness, hypothyroidism, pleural pathology, or medications. Documentation of hypoventilation requires **ANY** of the following:

- Increase in arterial partial pressure of carbon dioxide [PaCO₂] (or surrogate measure) to a value exceeding 55 mmHg for at least 10 minutes
- Greater than 10 mmHg increase in arterial PaCO₂ (or surrogate measure) during sleep (compared to an awake supine value) to a value exceeding 50 mmHg for at least 10 minutes
- Sleep oximetry from the complete sleep study tracing, rather than compressed data, which demonstrates oxygen saturation ≤ 88% for ≥ 5 consecutive minutes of nocturnal recording time (minimum recording time of 2 hours), recorded while breathing the individual's prescribed fraction of inspired oxygen (FiO₂)

INITIAL ATTENDED (SUPERVISED) SLEEP STUDY PERFORMED IN A SLEEP LAB

Inclusions:

In-lab (attended) sleep studies for individuals 18 years of age or older with suspected OSA:

An in-lab sleep (attended) study is established if the individual meets **EITHER** of the following criteria:

1. The initial unattended (unsupervised) study, performed in the past 3 years, was negative, inadequate (the reason for the inadequate/suboptimal HSAT is likely to recur on second attempt), equivocal or non-diagnostic and clinical suspicion for OSA remains **OR**
2. Individuals 18 years of age or older who have a contraindication to a home sleep study (see above Exclusions/Contraindications to HSAT^a) **AND** meet the following criteria:
 - a. Observed apneas during sleep; **OR**
 - b. A combination of **at least two (2)** of the following:
 - Excessive daytime sleepiness evidenced by an Epworth sleepiness >10, inappropriate daytime napping (e.g., during driving, conversation or eating), or sleepiness that interferes with daily activities and is not explained by other conditions;
 - Habitual snoring, defined as occurring every night or most nights per week, or gasping/choking episodes associated with awakenings;
 - Treatment-resistant hypertension (persistent hypertension in an individual taking 3 or more antihypertensive medications);
 - Obesity, defined as a body mass index (BMI) ≥30 kg/m² or neck circumference > 17 inches in men or >16 inches in women
 - Craniofacial or upper airway soft tissue abnormalities, including adenotonsillar hypertrophy, or neuromuscular disease
 - OR**
 - c. History of stroke (more than 30 days previously), transient ischemic attack, coronary artery disease, or sustained tachycardic or bradycardic arrhythmias in patients who meet **ONE** of the criteria listed under "b" above. **OR**
 - d. **Any** of the following conditions which may suggest OSA when the etiology is unclear:
 - i. right heart failure,
 - ii. polycythemia,
 - iii. sustained supraventricular or ventricular tachyarrhythmia occurring solely during sleep, **OR**
 - iv. pulmonary hypertension.

In-lab (attended) sleep studies for individuals 18 years of age or older with suspected sleep disorders other than OSA:

An in-lab supervised sleep study is established when there is suspicion of **ANY** of the following:

- Central sleep apnea (CSA)^b – to support the suspicion of CSA in this context, **ONE** of the following must be documented:
 - Heart failure,
 - Stroke within the preceding 90 days,
 - Chronic opiate or narcotic use,
 - Chiari malformation.
- Narcolepsy
- Nocturnal seizures
- Parasomnia which is likely to result in harm to the individual or others
- Idiopathic hypersomnia
- Periodic limb movement disorder^c (PLMD)--to support a suspicion of PLMD in this context, **ONE** of the following must be documented:
 - Pregnancy,
 - Renal failure,
 - Iron deficiency anemia,
 - Peripheral neuropathy,
 - Use of antidepressant or antipsychotic medications.
- Nocturnal desaturation (due to severe COPD or certain restrictive thoracic disorders)

^b *Note: OSA should be excluded before considering central sleep apnea (CSA) in individuals who snore.*

^c *Note: A diagnosis of PLMD requires that the individual have ongoing hypersomnia or insomnia. Individuals with OSA and/or restless leg syndrome should have these conditions optimally treated (as tolerated) before evaluation for PLMD.*

In-lab (attended) sleep studies for individuals younger than 18 years of age:

Inclusions:

- Individual is younger than 18 years of age and **any** of the following criteria are met:
 - Habitual snoring, defined as occurring every night or most nights per week, in association with **one or more** of criteria below:
 - Restless or disturbed sleep
 - Behavioral disturbance or learning disorders including deterioration in academic performance, attention deficit disorder, hyperactivity
 - Frequent awakenings
 - Enuresis (bedwetting)
 - Growth retardation or failure to thrive; **OR**
 - Excessive daytime somnolence or altered mental status not explained by other conditions; **OR**
 - Polycythemia not explained by other conditions; **OR**
 - Cor pulmonale not explained by other conditions; **OR**
 - Witnessed apnea with duration greater than two (2) respiratory cycles; **OR**
 - Nocturnal seizure; **OR**

- Labored breathing during sleep; **OR**
- Hypertrophy of the tonsils or adenoids in individuals at significant surgical risk such that the exclusion of OSA would allow avoidance of surgery; **OR**
- Suspected congenital central alveolar hypoventilation syndrome or sleep-related hypoventilation due to neuromuscular disease or chest wall deformities; **OR**
- Clinical evidence of a sleep-related breathing disorder in infants who have experienced an apparent life-threatening event; **OR**
- For exclusion of OSA in an individual who has undergone adenotonsillectomy for suspected OSA more than eight (8) weeks previously; **OR**
- The initial study was inadequate, equivocal or non-diagnostic and the child's parents or caregiver report that the breathing patterns observed at home were different from those during testing.

REPEAT ATTENDED (SUPERVISED) SLEEP STUDY PERFORMED IN A SLEEP LAB

Inclusions:

Repeat in-lab (attended) sleep study for individuals 18 years of age or older:

1. A follow-up in-lab sleep study is considered established for an individual with a diagnosis of OSA if **ANY** of the following apply:

- On one occasion following:
 - Upper airway surgery performed to treat OSA and/or improve compliance with PAP therapy in a patient with a contraindication to a HSAT
 - To assess efficacy of current settings of an oral appliance
 - To assess efficacy of current settings of a hypoglossal nerve stimulator
- To reevaluate the diagnosis of OSA and need for continued CPAP if there is significant weight loss (defined as 10% of body weight) since the most recent sleep study in an individual with exclusions/contraindications to HSAT(see above Exclusions/Contraindications to HSAT^a)
- Prior to implantation of a hypoglossal nerve stimulator in a patient who has not had a diagnostic study (home or lab) within the preceding 18 months
- Annual surveillance testing following hypoglossal nerve stimulator implantation

2. A follow-up in-lab sleep study is considered established for an individual with a diagnosis of OSA or other sleep disorder if **ANY** of the following apply:

- To titrate CPAP/BPAP in an individual meeting criteria of PAP therapy (see OSA-Non-surgical Treatment medical policy) with a contraindication to the use of APAP^d or for whom an attempt at APAP titration has been unsuccessful. Unsuccessful APAP titration will need to be supported by the downloaded CPAP data.
- To titrate CPAP/BPAP in an individual meeting criteria of PAP therapy (see OSA-Non-surgical Treatment medical policy) with a contraindication to the use of APAP^d (or has failed APAP re-titration) whose attempted split-night study did not adequately establish appropriate CPAP/BPAP treatment parameters
- To re-titrate CPAP/BPAP in an individual with a contraindication to the use of APAP^d (or has failed APAP re-titration) and has recurrence or worsening of symptoms despite PAP adherence as defined by CMS criteria (use of PAP for at least 4 hours per night on 70% of nights during a consecutive 30-day period).

^d Contraindications to the Use of Auto-adjusting Positive Airway Pressure (APAP)

- Congestive heart failure
- Moderate or severe chronic obstructive pulmonary disease: FEV1/FVC less than or equal to 0.7 and FEV1 less than 80% of predicted
- Chronic opiate use
- Use of supplemental oxygen for 24 hours daily
- Central sleep apnea (defined as having at least 50% central events or more than 5 central events per hour)
- Neuromuscular disorders (e.g., muscular dystrophy, myasthenia gravis)
- Obesity hypoventilation syndrome defined as a body mass index (BMI) greater than 30 kg/m² and hypoventilation which cannot be solely attributed to other conditions such as pulmonary disease, skeletal restriction, neuromuscular weakness, hypothyroidism, pleural pathology, or medications. Documentation of hypoventilation requires **ANY** of the following:
 - Increase in arterial PaCO₂ (or surrogate measure) to a value exceeding 55 mmHg for at least 10 minutes
 - Greater than 10 mmHg increase in arterial PaCO₂ (or surrogate measure) during sleep (compared to an awake supine value) to a value exceeding 50 mmHg for at least 10 minutes
 - Sleep oximetry from the complete sleep study tracing, rather than compressed data, demonstrates oxygen saturation ≤ 88% for ≥ 5 consecutive minutes of nocturnal recording time (minimum recording time of 2 hours), recorded while breathing the individual's prescribed FiO₂

Repeat in-lab (attended) sleep study for individuals younger than 18 years of age:

Inclusions:

A follow-up in-lab sleep study is considered established when **ANY** of the following apply:

- Initial study was inadequate, equivocal or non-diagnostic and the child's parents or caregiver report that the breathing patterns observed at home were different from those during testing.
- A patient with established OSA continues to exhibit persistent snoring or other symptoms of sleep disordered breathing despite PAP adherence as defined by CMS criteria (use of PAP for at least 4 hours per night on 70% of nights during a consecutive 30-day period)
- The patient has undergone adenotonsillectomy or other upper airway surgery more than 8 weeks previously for management of established OSA
- To reevaluate the diagnosis of OSA and need for continued PAP if there is significant weight loss (defined as 10% of body weight) since the most recent sleep study
- To initiate or titrate CPAP or BPAP in a patient whose diagnostic study confirms that the patient is a candidate for positive airway pressure therapy, and split-night study has not been performed or was inadequate:
- The initial sleep study has led to a diagnosis other than OSA and the repeat study is requested because of a change in clinical status or to assess efficacy after a change in therapy
- Prior to implantation of a hypoglossal nerve stimulator in a patient who has not had a diagnostic study (home or lab) within the preceding 18 months

EXCLUSIONS FOR SLEEP STUDIES

- When the above criteria are met
- Noninvasive pulse oximetry as a sole test (as an **alternative** to polysomnography or as a cardiorespiratory study) for diagnosing sleep related breathing disorders.
- Home sleep apnea studies performed with portable equipment with monitoring of three or fewer physiological parameters (type IV devices)

MUTIPLE SLEEP LATENCY TESTING (MSLT) AND MAINTENANCE OF WAKEFULNESS TESTING (MWT)

Inclusions:

Initial MSLT and/or MWT are considered established for suspected narcolepsy when **BOTH** of the following criteria are met:

- Excessive daytime sleepiness has been present for at least 8 weeks
- The patient has at least **ONE** of the following:
 - Disrupted nocturnal sleep
 - Cataplexy
 - Hallucinations (hypnagogic or hypnopompic)
 - Sleep paralysis

Note: It is expected that when MSLT/MWT is performed, polysomnography (PSG) will be performed on the preceding night. If PSG reveals that the individual has OSA, that should be treated before continuing the evaluation for narcolepsy.

Repeat MSLT and/or MWT are considered established for suspected narcolepsy when **BOTH** of the following criteria are met:

- Previous MSLT/MWT did not provide a diagnosis of narcolepsy
- The patient has continued symptoms suggestive of narcolepsy

Repeat MWT is considered established for occupational safety evaluation when **BOTH** of the following criteria are met:

- The patient has an established diagnosis of a sleep breathing disorder or narcolepsy
- The test is performed while on the current treatment to determine adequacy of therapy

MSLT and/or MWT are considered established for idiopathic hypersomnia when **BOTH** of the following criteria are met:

- Excessive daytime sleepiness has been present for at least 8 weeks
- The patient has at least **ONE** of the following:
 - Difficult morning awakening
 - Prolonged sleep during primary sleep period
 - Sleep drunkenness
 - Frequent non-refreshing daytime naps
 - The patient has undergone PSG or HSAT and symptoms persist despite adequate treatment of obstructive sleep apnea (if present)

CPT/HCPCS Level II Codes

Established codes:

95782	95783	95800	95801	95805	95806
-------	-------	-------	-------	-------	-------

Other codes (investigational, not medically necessary, etc.):

*May be covered for Medicare if criteria is met

94762

E0445

G0400*

Notes:

- *Code(s) may not be covered by all contracts or certificates. Please consult customer or provider inquiry resources at BCBSM or BCN to verify coverage.*
- *Individual policy criteria determine the coverage status of the CPT/HCPCS code(s) on this policy. Codes listed in this policy may have different coverage positions (such as established or experimental/investigational) in other medical policies.*

Background**OBSTRUCTIVE SLEEP APNEA**

Obstructive sleep apnea (OSA) syndrome is characterized by repetitive episodes of upper airway obstruction due to the collapse of the upper airway during sleep. This causes a drop in blood oxygenation and a brief arousal and can occur as frequently as every minute throughout the night. The main risk factors for OSA include obesity, male sex, older age, large neck size, instability of the respiratory control system, and craniofacial dysmorphisms; additional factors include cardiovascular disease, diabetes, and metabolic syndrome. OSA is associated with higher mortality because patients with OSA are more likely to have cardiac arrhythmias, coronary artery disease, congestive heart failure, stroke, diabetes, and treatment-resistant hypertension (persistent hypertension in a patient taking three or more antihypertensive medications). Since disorders linked to OSA are more common in ethnic minority groups, there are data supporting an increased risk of OSA in African Americans and American Indians.

The most common signs and symptoms in adults are snoring, excessive daytime sleepiness, and hypertension. Excessive daytime sleepiness may be subjective and is assessed by questionnaires such as the Epworth Sleepiness Scale, a short, self-administered questionnaire that asks individuals how likely they are to fall asleep in different scenarios such as watching TV, sitting quietly in a car, or sitting and talking to someone. Daytime sleepiness is uncommon in young children with OSA. Symptoms in children may include disturbed sleep and daytime neurobehavioral problems. In otherwise healthy children, OSA is usually associated with adenotonsillar hypertrophy and/or obesity.

The hallmark of OSA is snoring. During apneic episodes and the brief period of arousal that follows, an individual's snoring abruptly ceases and then resumes when the individual falls asleep again. The sleep fragmentation associated with repeated sleep disruption can lead to impairment of daytime activity. Adults with OSA-associated daytime somnolence are thought to be at higher risk for collisions involving motorized vehicles, i.e., cars, trucks, or heavy equipment, while OSA in children may result in neurocognitive impairment and behavioral problems.

OSA can also affect the cardiovascular and pulmonary systems.¹ For example, apnea leads to periods of hypoxemia, alveolar hypoventilation, hypercapnia, and acidosis. This in turn can cause systemic hypertension, cardiac arrhythmias, pulmonary hypertension, and cor

pulmonale. Systemic hypertension is common in individuals with OSA. Severe OSA is also associated with decreased survival, presumably related to severe hypoxemia, hypertension, or an increase in automobile collisions related to daytime sleepiness. It is estimated that about 7% of adults have moderate or severe OSA, and 20% have at least mild OSA, and individuals referred for evaluation of OSA represent only a small proportion of those who have clinically significant and treatable disease.¹

Diagnosis

Obstructive sleep apnea is widely underdiagnosed with up to 95% of individuals with clinically significant OSA reporting no prior OSA diagnosis. Moreover, underdiagnosis is particularly prevalent in Black individuals. The criterion standard diagnostic test for sleep disorders is a polysomnogram performed in a sleep laboratory.² A standard polysomnogram includes EEG, submental electromyogram (EMG) and electrooculogram (to detect rapid eye movement [REM] sleep) for sleep staging. Polysomnography (PSG) also typically includes electrocardiography and monitoring of respiratory airflow and effort, snoring, oxygen desaturation, and sleep position. An attended study ensures that the electrodes and sensors are functioning adequately and do not dislodge during the night. In addition, an attendant is able to identify severe OSA in the first part of the night and titrate continuous positive airway pressure (CPAP) in the second part of the night, commonly known as a “split-night” study. If successful, this strategy eliminates the need for an additional PSG for CPAP titration. Table 1 provides common respiratory events and respiratory event reporting terms and definitions.

Table 1. Definitions of Terms and Scoring Criteria for OSA

Terms	Definition
Respiratory event	
Apnea	The frequency of apneas and hypopneas is measured from channels assessing oxygen desaturation, respiratory airflow, and respiratory effort. In adults, apnea is defined as a drop in airflow by 90% or more of pre-event baseline for at least 10 seconds. Due to faster respiratory rates in children, pediatric scoring criteria define an apnea as 2 or more missed breaths, regardless of its duration in seconds.
Hypopnea	Hypopnea in adults is scored when the peak airflow drops by at least 30% of pre-event baseline for at least 10 seconds in association with either at least 3 or 4% decrease in arterial oxygen desaturation (depending on the scoring criteria) or an arousal. Hypopneas in children are scored by a 50% or greater drop in nasal pressure and either a 3% or more decrease in oxygen saturation or associated arousal.
RERA	Respiratory event-related arousal is defined as an event lasting at least 10 seconds associated with flattening of the nasal pressure waveform and/or evidence of increased respiratory effort, terminating in arousal but not otherwise meeting criteria for apnea or hypopnea
Respiratory event reporting	
AHI	The apnea/hypopnea index is the average number of apneas or hypopneas per hour of sleep
RDI	The respiratory disturbance index is the number of apneas, hypopneas, or respiratory event-related arousals per hour of sleep time. RDI is often used synonymously with the AHI.
REI	The respiratory event index is the number of events per hour of monitoring time. Used as an alternative to AHI or RDI in-home sleep studies when actual sleep time from EEG is not available.
OSA	Obstructive sleep apnea is repetitive episodes of upper airway obstruction due to the collapse and obstruction of the upper airway during sleep
Mild OSA	In adults: AHI or RDI of 5 to <15. In children: AHI ≥ 1 to <5
Moderate OSA	AHI or RDI of 15 to <30; Children: AHI of ≥ 5 to <10
Severe OSA	Adults: AHI or RDI ≥ 30 ; Children: AHI of ≥ 10
UARS	Upper airway resistance syndrome is characterized by a partial collapse of the airway and results in increased resistance to airflow. The increased respiratory effort is

	associated with multiple sleep fragmentations, as measured by very short alpha EEG arousals.
Positive airway pressure	
APAP	Auto-adjusting positive airway pressure may be used either to provide treatment or to determine the most effective pressure for CPAP
PAP	Positive airway pressure (PAP) may be continuous (CPAP) or auto-adjusting (APAP) or bi-level (bi-PAP). CPAP is a more familiar abbreviation for delivery of positive airway pressure.
PAP failure	Usually defined as an AHI greater than or equal to 15 events per hour while using CPAP
PAP intolerance	CPAP use for <4 hours per night for ≥5 nights per week, or refusal to use CPAP. CPAP intolerance may be observed in individuals with mild, moderate, or severe OSA

AHI: Apnea/hypopnea Index; APAP: auto-adjusting positive airway pressure; bi-PAP: bi-level positive airway pressure; CPAP: continuous positive airway pressure; EEG: electroencephalogram; OSA: obstructive sleep apnea; PAP: positive airway pressure; RDI: Respiratory Disturbance Index; REI: Respiratory Event Index; RERA: respiratory event-related arousal; UARS: upper airway resistance syndrome.

Sleep testing may be classified as follows:

- **Type I:** An attended sleep study performed in a hospital or freestanding sleep lab with continuous and simultaneous monitoring of electroencephalogram (EEG), electrooculogram (EOG), electrocardiogram (EKG), electromyogram (EMG), oxygen saturation, respiratory effort, and airflow. Type I studies are also known as polysomnography (PSG).
- **Type II:** A sleep study (usually unattended) performed with portable equipment with continuous and simultaneous monitoring of EEG, EOG, EKG, EMG, oxygen saturation, respiratory effort, and airflow. Type II studies are similar to type I (PSG) studies except that the former are usually performed in the home.
- **Type III:** An unattended sleep study performed with portable equipment with monitoring of a minimum of four channels: 2 respiratory movement/airflow, 1 ECG/heart rate and 1 oxygen saturation. The studies are performed in the home and differ from types I and II in that they do not provide data on sleep staging.
- **Type IV:** An unattended sleep study performed with portable equipment with monitoring of three or fewer physiological parameters only one of which is airflow. The studies are performed in the home and differ from types I and II in that they do not provide data on sleep staging.

Polysomnography (PSG) or home sleep apnea testing is ordered by a physician or qualified healthcare provider who has evaluated the individual and is managing the medical care of the individual, i.e., either a primary care physician or a specialist. Following the review of the sleep study results, recommendations for the most appropriate medical treatment may be made by the treating physician/QHP or may be a collaborative effort between the treating physician/QHP and the board-certified sleep medicine physician who interprets the results of the testing.

Facility/Provider Requirements

If an attended sleep study is performed in a non-hospital-based sleep laboratory, the laboratory must be accredited by the American Academy of Sleep Medicine (AASM).

An attended sleep study in a hospital-based sleep testing center must be accredited by AASM or an accreditation organization accepted under the Participating Hospital Agreement.

In order to perform and receive reimbursement for in-center and out-of-center sleep testing, a physician must be board-certified in sleep medicine by the American Board of Medical

Specialties or the American Board of Sleep Medicine. Any MD or DO may order a sleep test; however, it must be performed and interpreted by a physician who is board-certified in sleep medicine.

The technician performing the sleep testing must have one of the following certifications:

- American Board of Sleep Medicine, Registered Sleep Technologist, OR
- Board of Registered Polysomnographic Technologists, Registered Polysomnographic Technologist, OR
- National Board for Respiratory Care (any of the following):
 - Certified Pulmonary Function Technologist
 - Registered Pulmonary Function Technologist
 - Certified Respiratory Therapist
 - Registered Respiratory Therapist

Risk Factors for OSA

Although not an exclusive list, individuals with all 4 of the following symptoms are considered to be at high risk for obstructive sleep apnea (OSA):

- habitual snoring;
- observed apneas;
- excessive daytime sleepiness;
- a body mass index (BMI) greater than 30 kg/m².

If no bed partner is available to report snoring or observed apneas, other signs and symptoms suggestive of OSA (e.g., age of the individual, male gender, thick neck, craniofacial or upper airway soft tissue abnormalities, or unexplained hypertension) may be considered. Objective clinical prediction rules are being developed; however, at present, risk assessment is based primarily on clinical judgment.

The STOP-BANG questionnaire is a method developed for non-sleep specialists to assess the signs and symptoms of OSA (Snore, Tired, observed apnea, Blood Pressure, BMI, Age, Neck, Gender) and has been shown to have 97% sensitivity and 96% negative predictive value (specificity, 33%) for the identification of individuals with severe OSA (Apnea/Hypopnea Index [AHI] score >30 events per hour). Overnight oximetry has been used by some sleep specialists as a component of the risk assessment but is not adequate for the diagnosis of OSA.

Therefore, a follow-up polysomnography (PSG) or home sleep apnea test would still be required to confirm or exclude a diagnosis of OSA.

OSA in Children

The presentation of OSA in children may differ from that of adults. Children frequently exhibit behavioral problems or hyperactivity rather than daytime sleepiness. Obesity is defined as a body mass index greater than the 90th percentile for the weight/height ratio. Although the definition of severe OSA in children is not well established, an AHI or RDI greater than 1.5 events per hour is considered abnormal (an AHI or RDI of ≥ 10 events per hour may be considered severe).

Bariatric Surgery

Screening for OSA should be performed routinely in individuals scheduled for bariatric surgery, due to the high prevalence of OSA in this population. The optimal screening approach is not certain. An in-laboratory PSG or home sleep apnea test is the most accurate screening

method. Some experts recommend a symptom-based screening instrument, followed by PSG in individuals who exceed a certain threshold, as an alternative to performing PSG in all individuals. It should be noted that there is a high prevalence of obesity hypoventilation syndrome in individuals who are candidates for bariatric surgery. Therefore, obesity hypoventilation syndrome should be ruled out prior to home sleep apnea testing in this population.

Significant Weight Change

There is no established threshold for significant change in weight. Studies have reported improvements in OSA with an average weight loss of 10% of body weight.

Multiple Sleep Latency Test

The multiple sleep latency test (MSLT) is an objective measure of the tendency to fall asleep in the absence of alerting factors, while the maintenance of wakefulness test (MWT) is an objective measure of the ability to stay awake under soporific conditions (used to assess occupational safety). The MSLT and MWT are not routinely indicated in the evaluation and diagnosis of OSA or in assessment of change following treatment with continuous positive airway pressure (CPAP). The MSLT may be indicated as part of the evaluation of individuals with suspected narcolepsy to confirm the diagnosis (often characterized by cataplexy, sleep paralysis, and hypnagogic/hypnopompic hallucinations) or to differentiate between suspected idiopathic hypersomnia (characterized by difficult morning awakening, sleep drunkenness and constant somnolence but cataplexy is absent) and narcolepsy. Narcolepsy and OSA can co-occur. Because it is not possible to differentiate the excessive sleepiness caused by OSA and narcolepsy, OSA should be treated before confirming a diagnosis of narcolepsy with the MSLT.

Narcolepsy

Compared to obstructive sleep apnea (OSA), which affects 2% to 4% of the population, narcolepsy is a rare disease affecting 0.025 to 0.05%. Narcolepsy is a disorder characterized by excessive daytime sleepiness often associated with cataplexy, hypnagogic hallucinations, sleep paralysis or any combination of these symptoms. The excessive sleepiness of narcolepsy is characterized by repeated episodes of naps or lapses into sleep of short duration (usually less than one hour). The diagnosis of narcolepsy is usually confirmed by an overnight polysomnography (PSG) followed by MSLT. If the PSG shows evidence of OSA, this diagnosis should be treated before pursuing a diagnosis of narcolepsy.

Idiopathic hypersomnia

Daytime sleepiness following adequate (or even prolonged) nocturnal sleep duration and non-refreshing daytime naps are characteristic of idiopathic hypersomnia. Patients with idiopathic hypersomnia may have sleep paralysis and hallucination but cataplexy is absent. Despite prolonged sleep duration, patients with idiopathic hypersomnia display difficult morning awakening, sleep drunkenness and constant somnolence. Idiopathic hypersomnia is rarer than narcolepsy and tends to be more resistant to treatment. A diagnosis of idiopathic hypersomnia requires exclusion of other causes of fatigue and excessive daytime sleepiness including hypothyroidism, depression, obstructive sleep apnea, etc. Patients who have undergone diagnostic testing for OSA and whose AHI is >5 should be adequately treated for OSA before undergoing evaluation for other causes of hypersomnia.

Split-Night Studies

American Academy of Sleep Medicine (AASM) practice parameters indicate that a split-night study (initial diagnostic PSG followed by CPAP titration during PSG on the same night) is an alternative to 1 full night of diagnostic PSG followed by a second night of titration if the following 4 criteria are met:

- a. An AHI of at least 40 is documented during a minimum of 2 hours of diagnostic PSG. Split-night studies may sometimes be considered at an AHI of 20 to 40 events per hour, based on clinical judgment (e.g., if there are also repetitive long obstructions and major desaturations). However, at AHI values below 40, determination of CPAP-level requirements, based on split-night studies, may be less accurate than in full-night calibrations.
- b. CPAP titration is carried out for more than 3 hours (because respiratory events can worsen as the night progresses).
- c. PSG documents that CPAP eliminates or nearly eliminates the respiratory events during rapid eye movement (REM) and non-REM sleep, including REM sleep with the individual in the supine position.
- d. A second full night of PSG for CPAP titration is performed if the diagnosis of a sleep-related breathing disorder (SRBD) is confirmed, but criteria b and c are not met.

A variety of devices have been developed specifically to evaluate OSA at home. They range from portable full PSG systems to single channel oximeters. Available devices evaluate different parameters, which may include oximetry, respiratory and cardiac monitoring, and sleep/wake activity, but most portable monitors do not record EEG activity.

Surgical management of OSA (i.e., adenotonsillectomy, uvulopalatopharyngoplasty, orthognathic surgery) is discussed in the policy titled “Obstructive Sleep Apnea and Snoring – Surgical Treatment.”

Summary of Evidence

For individuals who have suspected obstructive sleep apnea (OSA) who receive home sleep apnea testing with at least three recording channels, the evidence includes randomized controlled trials (RCTs). Relevant outcomes are test accuracy, symptoms, functional outcomes, and resource utilization. Randomized controlled trials have reported that home sleep apnea testing (with sensors for respiratory effort, airflow, and oxygen saturation, or alternatively with peripheral arterial tone [PAT], actigraphy and oxygen saturation) is noninferior to testing in the sleep lab for adults with a high pretest probability of OSA and absence of comorbid conditions as determined by clinical evaluation. A positive portable monitoring study with channels that include arterial oxygen saturation, airflow, and respiratory effort has a high positive predictive value for OSA and can be used as the basis for a continuous positive airway pressure (CPAP) trial to determine efficacy of treatment. A negative portable monitoring study cannot be used to rule out OSA. Individuals who have a negative result from portable monitoring or have a positive study but do not respond to CPAP should undergo further evaluation. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have suspected OSA who receive limited channel home sleep apnea testing, the evidence includes studies on diagnostic accuracy. Relevant outcomes are test

accuracy, symptoms, functional outcomes, and resource utilization. The ability to detect clinically significant OSA without sensors for respiratory effort, airflow, and oxygen saturation, or alternatively without peripheral arterial tone, actigraphy and oxygen saturation, lacks support in the literature. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Rationale

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to individuals and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms. The following is a summary of the key literature to date.

MULTICHANNEL HOME SLEEP APNEA TESTING

Table 2. Health Outcome Measures Relevant to OSA

Outcome	Measure	Description	Clinically Meaningful Difference (If Known)
Change in AHI	AHI	Mean change in AHI from baseline to posttreatment	Change from severe-to-moderate or mild OSA
AHI success	Percentage of individuals achieving success	Studies may use different definitions of success, but the most common for AHI success is the Sher criteria	Sher criteria include a decrease in AHI of $\geq 50\%$ and an AHI < 20 events per hour. Alternative measures of success may be AHI < 15 , < 10 , or < 5 events per hour
ODI	Oxygen levels in blood during sleep	The number of times per hour of sleep that the blood oxygen level drops by ≥ 4 percentage points	More than 5 events per hour
ESS	Scale ranges from 0 to 24	The ESS is a short, self-administered questionnaire that asks individuals how likely they are to fall asleep in 8 different situations (e.g., watching TV, sitting quietly in a car, or sitting and talking to someone)	An ESS of ≥ 10 is considered excessively sleepy
FOSQ	30 questions	Disease-specific quality of life questionnaire that evaluates functional status related to excessive sleepiness	A score of ≥ 18 is the threshold for normal sleep-related functioning, and a change of ≥ 2 points is considered a clinically meaningful improvement

AHI: Apnea/Hypopnea Index; ESS: Epworth Sleepiness Score; FOSQ: Functional Outcomes of Sleep Questionnaire; ODI: Oxygen Desaturation Index; OSA: obstructive sleep apnea.

Systematic Reviews

Balk et al (2011) conducted a comparative effectiveness review for the Agency for Healthcare Research and Quality (AHRQ) on the diagnosis and treatment of OSA in adults.⁴ Reviewers found strong evidence that an AHI greater than 30 events per hour is an independent predictor of all-cause mortality, with low or insufficient evidence for an association between AHI and other clinical outcomes. Reviewers found moderate evidence that type 3 and type 4 monitors may have the ability to accurately predict an AHI suggestive of OSA and that type 3 monitors perform better than type 4 monitors at AHI cutoffs of 5, 10, and 15 events per hour.

Randomized Controlled Trials

Home sleep testing with three recording channels that include respiratory effort, airflow, and oxygen saturation, but not heart rate, are considered by some, including the Centers for Medicare & Medicaid, to be sufficient for home sleep studies. Corral et al (2017) reported a multicenter noninferiority trial of home sleep testing using a 3-channel monitor compared with in-laboratory PSG in 430 patients.⁵ Included in the study were patients referred to tertiary hospitals in Spain for suspected OSA, who had snoring or sleep apneas observed by a partner, ESS score of ten or greater, and absence of clinical suspicion of any other sleep pathology. Both groups of patients who were diagnosed with OSA received continuous positive airway pressure (CPAP) titration with a single auto-adjusting positive airway pressure (APAP) session at home. The median baseline ESS score was 13 in both groups. CPAP was indicated in 68% of patients in the PSG arm compared with 53% in the home sleep testing group, with the difference attributed to the underestimation of AHI in home sleep studies. All patients, including those treated with CPAP and those who were not, were assessed at six-month follow-up. ESS score improved by -4.2 (95% confidence interval [CI], -4.8 to -3.6) in the home sleep testing group and by -4.9 (95% CI, -5.4 to -4.3) in the PSG group. With a noninferiority margin of two points on the ESS, home sleep testing was noninferior to in-laboratory PSG.

Section Summary: Multichannel Home Sleep Apnea Testing

Based on this evidence and society guidelines, portable monitoring with a minimum of four recording channels (including oxygen saturation, respiratory movements, airflow, and electrocardiogram or heart rate), or with a device that measures peripheral arterial tone, actigraphy, and oxygen saturation, for diagnosis of OSA in adults who are at high risk for OSA improves outcomes, when clinical evaluation and follow-up are conducted by a medical professional experienced in the diagnosis and treatment of sleep disorders.

LIMITED CHANNEL HOME SLEEP APNEA TESTING

Use of Auto-Adjusting Positive Airway Pressure for Diagnosis and Treatment Supervised by a Sleep Specialist

Randomized Controlled Trials

Mulgrew et al (2007) published a randomized validation study of the diagnosis and management of OSA with a single-channel monitor followed by auto-adjusting positive airway pressure (APAP).⁶ They developed a diagnostic algorithm that had a 94% positive predictive value (PPV) for moderate-to-severe OSA assessed by PSG. Patients who passed the screening (n=68) were randomized to attended in-laboratory PSG with CPAP titration or to home monitoring with a portable APAP unit. No difference was observed between lab-PSG and home-managed patients for any of the outcome measures. Senn et al (2006) assessed whether an empiric approach, using a two-week trial of APAP, could effectively diagnose OSA.⁷ Patients (n=76) were included in the study if they had been referred by primary care physicians for evaluation of suspected OSA, were habitual snorers, complained of daytime sleepiness, and had an ESS score of 8 or greater (mean, 13.6). At the end of the two-week trial, patients were asked to rate the perceived effect of treatment and to indicate whether they had used CPAP for more than two hours per night and were willing to continue treatment. Patients without a clear benefit of CPAP received further evaluation, including clinical

assessment and PSG. Compared with PSG, patient responses showed a sensitivity of 80%, a specificity of 97%, a positive predictive value of 97%, and a negative predictive value of 78%. Berry et al (2008) randomized 106 patients referred for a sleep study for suspected OSA at a local Veterans Administration center to portable monitoring followed by APAP or to PSG for diagnosis and treatment.⁸ Patients were screened with a detailed sleep and medical history questionnaire, and patients on α -blockers or not in sinus rhythm were excluded due to the type of portable monitoring device used (Watch-PAT™ 100). Of the 53 patients randomized to PSG, 6 (11%) did not have PSG-defined OSA; in the portable monitoring arm, 4 (8%) of 53 patients were found not to have OSA. Treatment outcomes were similar in both groups, with a 7-point improvement in ESS score, 3-point improvement in the Functional Outcomes of Sleep Questionnaire score, and a machine estimate of residual AHI of 3.5 events per hour in the portable monitoring APAP group and 5.3 in the PSG group.

Apnea Risk Evaluation System

Nonrandomized Comparative Studies

Ayappa et al (2008) reported on a validation study of a small apnea monitor that is self-applied to the forehead.⁹ The device measures blood oxygen saturation and pulse rate, airflow, snoring levels, head movement, and head position. The study enrolled 80 individuals with a high likelihood of OSA and 22 with a low risk of OSA; results of simultaneous Apnea Risk Evaluation System (ARES) recording and PSG were available for 92 individuals. When healthy subjects were excluded from the analysis, sensitivity (91%) and specificity (92%) were relatively high for an AHI of 15 or more events per hour but dropped considerably with an AHI between 5 and 15 (sensitivity, 97%; specificity, 78%). Five percent of the subjects could not tolerate the device and were not included in the analysis.

Sleep Image System

Randomized Controlled Trials

The Sleep Image System is cloud-based software as a medical device that generates AHI from data recorded with a single photo plethysmogram sensor. The SleepImage algorithms calculate heart rate variability, respiration, and oxygen saturation with cardiopulmonary coupling analysis. Hilmisson et al (2020) compared results calculated by the SleepImage System with manually scored PSG in 805 children ages 5 to 9.9 yrs. of age who participated in the Childhood Adenotonsillectomy Trial (CHAT).¹⁰ The CHAT study included 1244 habitually snoring children who were referred for PSG. A total of 805 children had successfully collected data from the sensor. Concordance between the SleepImage-derived AHI and PSG-derived AHI is shown in Table 3. Kappa was 0.81, 0.89, and 0.91 for mild, moderate, and severe sleep apnea, respectively. A proposed benefit is that this would be easier for children compared to a test requiring multiple sensors and improve access. Further study in a wider population is needed to evaluate whether this system might be a suitable method for evaluating sleep parameters in the home.

Table 3. Clinical Validity of the SleepImage System

Study	Initial N	Final N	Excluded Samples	Prevalence of Condition	Clinical Validity: Agreement (95% CI)
-------	-----------	---------	------------------	-------------------------	---------------------------------------

					Mild Sleep Apnea AHI > 1.0	Moderate Sleep Apnea AHI > 5.0	High Risk AHI > 10.0
Hilmisson et al (2020)	1244	805	439	64%	0.914 (0.895 to 0.934)	0.967 (0.954 to 0.979)	0.986 (0.978 to 0.994)

CI: confidence interval

Section Summary: Limited Channel Home Sleep Apnea Testing

The evidence for limited channel home sleep apnea testing (includes type four monitors) in patients who have OSA consists of studies on diagnostic accuracy. A number of questions remain about the ability of these home sleep apnea tests to detect clinically significant OSA without sensors for respiratory effort, airflow, and oxygen saturation (or alternatively, peripheral arterial tone, actigraphy, and oxygen saturation).

Supplemental Information

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Clinical Input From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Sleep Medicine

AASM (2017) published clinical practice guidelines on diagnostic testing for adult OSA.¹¹ AASM provided the following recommendations (Table 4).

Table 4. Recommendations on Diagnostic Testing for Adult OSA

Recommendation Statement	SOR	QOE	Benefits vs Harms
We recommend that clinical tools, questionnaires, and prediction algorithms not be used to diagnose OSA in adults, in the absence of PSG or HSAT	Strong	Moderate	High certainty that harms outweigh benefits
We recommend that PSG, or HSAT with a technically adequate device, be used for the diagnosis of OSA in uncomplicated adult patients presenting with signs and symptoms that indicate an increased risk of moderate to severe OSA.	Strong	Moderate	High certainty that benefits outweigh harms
We recommend that if a single HSAT is negative, inconclusive, or technically inadequate, PSG be performed for the diagnosis of OSA.	Strong	Low	High certainty that benefits outweigh harms
We recommend that PSG, rather than home sleep testing, be used for patients with significant cardiorespiratory disorder, potential respiratory muscle weakness, awake or suspected sleep	Strong	Very low	High certainty that benefits outweigh harms

hypoventilation, chronic opioid medication use, history of stroke or severe insomnia.

We suggest that, if clinically appropriate, a split-night diagnostic protocol, rather than a full- night diagnostic protocol for PSG be used for the diagnosis of OSA	Weak	Low	Low certainty that benefits outweigh harms
We suggest that when the initial PSG is negative, and there is still clinical suspicion for OSA, a second PSG be considered for the diagnosis of OSA.	Weak	Very low	Low certainty that benefits outweigh harms

HSAT: home sleep apnea testing; OSA: obstructive sleep apnea; PSG: polysomnography; QOE: quality of evidence; SOR: strength of recommendation.

The AASM considers a technically adequate home sleep apnea test (HSAT) device to incorporate "a minimum of the following sensors: nasal pressure, chest and abdominal respiratory inductance plethysmography, and oximetry; or else PAT [peripheral arterial tone] with oximetry and actigraphy." The guidelines refer to the AASM Manual for the Scoring of Sleep and Associated Events for additional information regarding HSAT sensor requirements. In 2021, the AASM published a guidance statement that focuses on indications for follow-up sleep apnea testing with PSG or home sleep apnea tests in individuals with OSA.¹² The following clinical guidance statements were provided:

- "Follow-up PSG or HSAT is not recommended for routine reassessment of asymptomatic individuals with obstructive sleep apnea on PAP therapy, however, follow-up PSG or HSAT can be used to reassess patients with recurrent or persistent symptoms, despite good PAP [positive airway pressure] adherence.
- Follow-up PSG or HSAT is recommended to assess response to treatment with non-PAP interventions.
- Follow-up PSG or HSAT may be used if clinically significant weight gain or loss has occurred since diagnosis of OSA or initiation of its treatment.
- Follow-up PSG may be used for reassessment of sleep-related hypoxemia and/or sleep-related hypoventilation following initiation of treatment for OSA.
- Follow-up PSG or HSAT may be used in patients being treated for OSA who develop or have a change in cardiovascular disease.
- Follow-up PSG may be used in patients with unexplained PAP device-generated data."

The AASM also issued guidelines in 2009 on the evaluation, management, and long-term care of adults with OSA.¹³ The levels of recommendation are "standard" (generally accepted patient-care strategy, with high degree of certainty; level 1 to 2 evidence), "guideline" (moderate degree of clinical certainty; level 2 to 3 evidence), or "option" (uncertain clinical use; insufficient or inconclusive evidence).

American Academy of Pediatrics

The American Academy of Pediatrics (AAP; 2012) published guidelines on the diagnosis and management of uncomplicated childhood OSA associated with adenotonsillar hypertrophy and/or obesity in an otherwise healthy child treated in the primary care setting, which updated AAP's 2002 guidelines.^{14,15} AAP recommended that all children or adolescents be screened for snoring, and PSG be performed in children or adolescents with snoring and symptoms or signs of OSA as listed in the guideline. If PSG is not available, an alternative diagnostic test or referral to a specialist, may be considered (option). The estimated prevalence rates of OSA in children or adolescents ranged from 1.2% to 5.7%.

American Society of Metabolic and Bariatric Surgery

The American Society of Metabolic and Bariatric Surgery (2012) published guidelines on the perioperative management of OSA (reviewed in October 2015).¹⁶ The guidelines noted that while some reports in the literature have recommended routine screening for OSA prior to bariatric surgery, other reports have suggested clinical screening only does not result in any increase in postoperative pulmonary complications after laparoscopic Roux-en-Y gastric bypass, and that most current surgical practices refer patients with clinical symptoms of OSA for PSG, but do not make this a routine preoperative test prior to bariatric surgery. The society provided, based on the evidence in the literature to date, the following guidelines on OSA in the bariatric surgery patient and its perioperative management:

- "OSA is highly prevalent in the bariatric patient population...."
- [Patients with moderate to severe OSA] should bring their CPAP machines, or at least their masks, with them at the time of surgery and use them following bariatric surgery at the discretion of the surgeon.
- Routine pulse oximetry or capnography for postoperative monitoring of patients with OSA after bariatric surgery should be utilized, but the majority of these patients do not routinely require an ICU [intensive care unit] setting.
- No clear guidelines exist upon which to base recommendations for retesting for OSA following bariatric surgery...."

American Heart Association

In 2021, the American Heart Association (AHA) published a scientific statement on OSA and cardiovascular disease.¹⁷ The treatment options for OSA and eligibility for their use are described in the statement.

Recommendations for screening for OSA are as follows:

- "We recommend screening for OSA in patients with resistant/poorly controlled hypertension, pulmonary hypertension, and recurrent atrial fibrillation after either cardioversion or ablation."
- "In patients with New York Heart Association class II to IV heart failure and suspicion of sleep-disordered breathing or excessive daytime sleepiness, a formal sleep assessment is reasonable."
- "In patients with tachy-brady syndrome or ventricular tachycardia or survivors of sudden cardiac death in whom sleep apnea is suspected after a comprehensive sleep assessment, evaluation for sleep apnea should be considered."
- "After stroke, clinical equipoise exists with respect to screening and treatment."

U.S. Preventive Services Task Force Recommendations

The U.S. Preventive Services Task Force (2022) reported on the evidence for screening for OSA in adults and concluded that "the current evidence is insufficient to assess the balance of benefits and harms of screening for obstructive sleep apnea in the general adult population. Evidence on screening tools to accurately detect persons in the general adult population at increased risk of OSA who should receive further testing and treatment is lacking"^{18,19}

Ongoing and Unpublished Clinical Trials

A search of ClinicalTrials.gov identified over 100 studies on the diagnosis of OSA.

Regulatory Status

The novel Sleep Image System for diagnosis of OSA is described in Table 5.

Table 5. Novel Devices for OSA Diagnosis

Device	Manufacturer	Description	FDA Marketing Clearance	FDA Product Code	Year
Diagnosis					
Sleep Image System	MyCardio	Software as a medical device that provides automated analysis of sleep data from a single photoplethysmogram sensor to aid in the evaluation of sleep disorders.	K163696	MNR	2017

FDA: Food and Drug Administration; OSA: obstructive sleep apnea

Government Regulations

National:

National Coverage Determination (NCD) for Sleep Testing for Obstructive Sleep Apnea (OSA) (240.4.1)

Effective Date: 3/3/09; Implementation Date 8/10/09

Indications and Limitations of Coverage

Nationally Covered Indications

Effective for claims with dates of service on and after March 3, 2009, the Centers for Medicare & Medicaid Services finds that the evidence is sufficient to determine that the results of the sleep tests identified below can be used by a beneficiary's treating physician to diagnose OSA, that the use of such sleep testing technologies demonstrates improved health outcomes in Medicare beneficiaries who have OSA and receive the appropriate treatment, and that these tests are thus reasonable and necessary under section 1862(a) (1) (A) of the Social Security Act.

- Type I PSG is covered when used to aid the diagnosis of OSA in beneficiaries who have clinical signs and symptoms indicative of OSA if performed attended in a sleep lab facility.
- Type II or Type III sleep testing devices are covered when used to aid the diagnosis of OSA in beneficiaries who have clinical signs and symptoms indicative of OSA if performed unattended in or out of a sleep lab facility or attended in a sleep lab facility.
- Type IV sleep testing devices measuring three or more channels, one of which is airflow, are covered when used to aid the diagnosis of OSA in beneficiaries who have signs and symptoms indicative of OSA if performed unattended in or out of a sleep lab facility or attended in a sleep lab facility.
- Sleep testing devices measuring three or more channels that include actigraphy, oximetry, and peripheral arterial tone, are covered when used to aid the diagnosis of OSA in beneficiaries who have signs and symptoms indicative of OSA if performed unattended in or out of a sleep lab facility or attended in a sleep lab facility.

Nationally Non-Covered Indications

Effective for claims with dates of services on and after March 3, 2009, other diagnostic sleep tests for the diagnosis of OSA, other than those noted above for prescribing CPAP, are not sufficient for the coverage of CPAP and are not covered.

Local:

Wisconsin Physicians Service Insurance Corporation (WPS)

Local Coverage Determination (LCD): Polysomnography and Other Sleep Studies (L36839)

Original Effective Date: 02/16/2017; Revision Effective Date: 06/26/2025

Coverage Indications, Limitations, and/or Medical Necessity

Sleep Studies and Polysomnography (PSG) refers to the continuous and simultaneous monitoring and recording of various physiological and pathophysiological parameters of sleep furnished in a sleep laboratory facility that includes physician review, interpretation and report. A technologist is physically present to supervise the recording during sleep time and has the ability to intervene, if needed. The studies are performed to diagnose a variety of sleep disorders and to evaluate a patient's response to therapies such as continuous positive airway pressure (CPAP). PSG is distinguished from sleep studies by the inclusion of sleep staging.

Please refer to CMS publication 100-02 *Medicare Benefit Policy Manual*, Chapter 15 Covered Medical and Other Health Services, Section 70 Sleep Disorder Clinics for guidance: sleep disorder clinics may be hospital-affiliated or freestanding clinics, for conditions diagnosed through the study of sleep, therapy and research which are covered under Medicare.

Polysomnography Testing

Polysomnography (PSG) includes sleep staging, which requires items 1 through 3 below. Polysomnography is defined to minimally include, but is not limited to, the following:

- A 1-4 lead electroencephalogram (EEG) to measure global neural encephalographic activity using electrodes placed on the scalp.
- Electrooculogram (EOG) to measure eye movements using electrodes placed near the outer canthus of each eye.
- A submental electromyogram (EMG) to measure submental electromyographic activity using electrodes placed over the mentalis, submental muscle, and/or masseter regions.
- Rhythm electrocardiogram (ECG).
- Nasal and/or oral airflow via both thermistor and nasal pressure sensor.
- Respiratory effort by chest-wall and abdominal movement measured using respiratory inductive plethysmography, endoesophageal pressure or intercostal EMG.
- Gas exchange (oxygen saturation [SpO2]) by oximetry or transcutaneous monitoring.
- Bilateral anterior tibialis muscle activity, motor activity-movement using EMG.
- Body positions by directly applied sensors or by direct observation.

PSG and other sleep test monitoring devices are generally classified based on the number of biologic sensors applied and physiologic parameters recorded.

Criteria for Coverage of Diagnostic Tests

Please refer to CMS publication 100-02 *Medicare Benefit Policy Manual*, Chapter 15 Covered Medical and Other Health Services, Section 70 Sleep Disorder Clinics, Subsection A. Criteria for Coverage of Diagnostic Tests and Subsection B. Medical Conditions for Which Testing is Covered.

In order to bill claims for diagnostic tests the reasonable and necessary medical conditions will be covered when listed criteria is met:

- Sleep disorder clinics may be hospital-affiliated or freestanding clinics with physician direction and control. Routine diagnostic sleep testing may be performed in the absence of physician direct supervision.
- Sleep disorder clinics will maintain the attending physician's orders/referrals.
- Documentation will support the medical evidence for the need of diagnostic testing, e.g., the signs, symptoms, concerns, or complaints in order for diagnostic testing to be covered, e.g., physician examinations and laboratory tests.

The Social Security Act 1862(a)(1)(A) does not support duplicative diagnostic testing by the attending physician to the extent the results remain pertinent, as not reasonable and necessary.

Medical Conditions for Which Testing is Covered

- **Sleep Apnea** - Apnea is defined as a cessation of airflow for at least 10 seconds. Hypopnea is defined as an abnormal respiratory event lasting at least 10 seconds with at least a 30% reduction in thoracoabdominal movement or airflow as compared to baseline, and with at least a 4% oxygen desaturation. This is a potentially lethal condition where the patient stops breathing during sleep. Three types of sleep apnea have been described (central, obstructive, and mixed). The nature of the apnea episodes can be documented by appropriate diagnostic testing.

Diagnostic testing is covered only if the patient has the symptoms or complaints of one of the conditions listed below.

- **Obstructive Sleep Apnea (OSA)** is the collapse of the oropharyngeal walls and the obstruction of airflow occurring during sleep.

CMS PUB 100-03 NCD Chapter 1, Section 240.4.1

Sleep Testing for Obstructive Sleep Apnea (OSA) finds that the evidence is sufficient to determine that the results of the sleep tests identified below can be used by a beneficiary's treating physician to diagnose OSA.

- a. **Type I PSG** is covered when used to aid the diagnosis of OSA in beneficiaries who have clinical signs and symptoms indicative of OSA if performed attended in a sleep lab facility.
 - The most comprehensive is designated Type I attended facility-based polysomnography (PSG), which is considered the reference standard for diagnosing OSA. Attended facility based polysomnogram is a comprehensive diagnostic sleep test including at least electroencephalography (EEG), electro-oculography (EOG), electromyography (EMG), heart rate or electrocardiography (ECG), airflow, breathing/respiratory effort, and arterial oxygen saturation (SaO₂) furnished in a sleep laboratory facility in which a technologist supervises the recording during sleep time and has the ability to intervene if needed.
 - Overnight PSG is the conventional diagnostic test for OSA. The American Thoracic Society and the American Academy of Sleep Medicine have

recommended supervised PSG in the sleep laboratory over 2 nights for the diagnosis of OSA and the initiation of continuous positive airway pressure (CPAP).

- b. **Type II sleep testing devices** are covered when used to aid the diagnosis of OSA in beneficiaries who have clinical signs and symptoms indicative of OSA if performed unattended in or out of a sleep lab facility or attended in a sleep lab facility.
 - Type II monitors have a minimum of 7 channels (e.g., EEG, EOG, EMG, ECG-heart rate, airflow, breathing/respiratory effort, SaO₂)-this type of device monitors sleep staging, so AHI can be calculated).
- c. **Type III sleep testing devices** are covered when used to aid the diagnosis of OSA in beneficiaries who have clinical signs and symptoms indicative of OSA if performed unattended in or out of a sleep lab facility or attended in a sleep lab facility.
 - Type III monitors have a minimum of 4 monitored channels including ventilation or airflow (at least two channels of respiratory movement or respiratory movement and airflow), heart rate or ECG, and oxygen saturation.
- d. **Type IV sleep testing devices** measuring three or more channels, one of which is airflow, are covered when used to aid the diagnosis of OSA in beneficiaries who have signs and symptoms indicative of OSA if performed unattended in or out of a sleep lab facility or attended in a sleep lab facility.
 - Type IV devices may measure one, two, three or more parameters but do not meet all the criteria of a higher category device.
 - Sleep testing devices measuring three or more channels that include actigraphy, oximetry, and peripheral arterial tone, are covered when used to aid the diagnosis of OSA in beneficiaries who have signs and symptoms indicative of OSA if performed unattended in or out of a sleep lab facility or attended in a sleep lab facility.

- **Narcolepsy** - *This term refers to a syndrome that is characterized by abnormal sleep tendencies, e.g., excessive daytime sleepiness or disturbed nocturnal sleep. Related diagnostic testing is covered if the patient has inappropriate sleep episodes or attacks (e.g., while driving, in the middle of a meal, in the middle of a conversation), amnesiac episodes, or continuous disabling drowsiness.*

CMS Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 70.

- The diagnosis of narcolepsy is usually confirmed by an overnight sleep study (polysomnography) followed by a multiple sleep latency test (MSLT). MSLT involves several 20-minute nap opportunities offered at 2-hour intervals. MSLT objectively assesses sleep tendency by measuring the number of minutes it takes the patient to fall asleep. Conversely, the maintenance of wakefulness test (MWT) requires the patient to try to stay awake.
- MSLT is the better test for demonstration of sleep-onset REM periods, a determination that is important in establishing the diagnosis of narcolepsy. To ensure validity, proper interpretation of the MSLT can only be made following a polysomnography performed on the preceding night.
- The following measurements are normally required to diagnose narcolepsy:

- Polysomnographic assessment of the quality and quantity of nighttime sleep;
 - Determination of the latency of the first REM episode
 - MSLT; and
 - The presence of REM-sleep episodes.
- Initial polysomnography and MSLT occasionally fail to identify narcolepsy.
 - Repeat polysomnography may be indicated:
 - if the first study is technically inadequate due to equipment failure;
 - if the subject could not sleep or slept for an insufficient amount of time to allow a clinical diagnosis;
 - if initiation of therapy or confirmation of the efficacy of prescribed therapy is needed; or
 - if the results were inconclusive or ambiguous.
- **Impotence** – will not be addressed in this LCD. See CMS Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 70 for coverage of impotence.
- **Parasomnia** - Parasomnias are a group of conditions that represent undesirable or unpleasant occurrences during sleep. Behavior during these times can often lead to damage to the surroundings and injury to the patient or to others. Parasomnia may include conditions such as sleepwalking, sleep terrors, and rapid eye movement (REM) sleep behavior disorders. In many of these cases, the nature of these conditions may be established by careful clinical evaluation. Suspected seizure disorders as possible cause of the parasomnia are appropriately evaluated by standard or prolonged sleep EEG studies. In cases where seizure disorders have been ruled out and in cases that present a history of repeated violent or injurious episodes during sleep, polysomnography may be useful in providing a diagnostic classification or prognosis.

Split-Night Studies

- For Continuous Positive Airway Pressure (CPAP) titration, a split-night study (initial diagnostic polysomnogram followed by CPAP titration during polysomnography on the same night) is an alternative to one full night of diagnostic polysomnography, followed by a second night of titration for the treatment of obstructive sleep apnea (OSA) if the following criteria are met.

Continuous Positive Airway Pressure (CPAP) is a non-invasive technique for providing single levels of air pressure from a flow generator, via a nose mask, through the nares. The purpose is to prevent the collapse of the oropharyngeal walls and the obstruction of airflow during sleep, which occurs in obstructive sleep apnea (OSA).

- A positive test for OSA is established if either of the following criteria using the Apnea-Hypopnea Index (AHI) or Respiratory Disturbance Index (RDI) are met:
 - AHI or RDI greater than or equal to 15 events per hour with a minimum of 30 events;
or
 - AHI or RDI greater than or equal to 5 and less than or equal to 14 events per hour with a minimum of 10 events and documented symptoms of excessive daytime sleepiness, impaired cognition, mood disorders or insomnia, or documented hypertension, ischemic heart disease, or history of stroke.

The AHI is equal to the average number of episodes of apnea and hypopnea per hour.
The RDI is equal to the average number of respiratory disturbances per hour.

If the AHI or RDI is calculated based on less than 2 hours of continuous recorded sleep, the total number of recorded events to calculate the AHI or RDI during sleep testing is at least the number of events that would have been required in a 2-hour period.

- CPAP titration is carried out for more than three hours; and
- Polysomnography documents that CPAP eliminates, or nearly eliminates, the respiratory events during REM and NREM sleep.

Follow-up polysomnography or a cardio-respiratory sleep study is indicated for the following conditions:

- To evaluate the response to treatment (CPAP, oral appliances or surgical intervention);
- After substantial weight loss has occurred in patients on CPAP for treatment of sleep-related breathing disorders to ascertain whether CPAP is still needed at the previously titrated pressure;
- After substantial weight gain has occurred in patients previously treated with CPAP successfully, who are symptomatic again despite continued use of CPAP, to ascertain whether pressure adjustments are needed; or
- When clinical response is insufficient or when symptoms return despite a good initial response to treatment with CPAP.

Home Sleep Testing

- The physician services related to home sleep testing (G0398, G0399 and G0400) are covered for the purpose of testing a patient for the diagnosis of obstructive sleep apnea if the home sleep testing is reasonable and necessary for the diagnosis of the patient's condition, meets all other Medicare requirements, and the physician who performs the service has sufficient training and experience to reliably perform the service.
(See Physician requirements below) (See Billing and Coding: **POLYSOMNOGRAPHY** and Other Sleep Studies)
- A home sleep test is covered only when it is performed in conjunction with a comprehensive sleep evaluation and in patients with a high pretest probability of moderate to severe obstructive sleep apnea.
- Home sleep testing is not covered for persons with comorbidities (moderate to severe pulmonary disease, neuromuscular disease or congestive heart failure).
- Home Sleep studies are only covered for the diagnosis of Obstructive Sleep Apnea. They are not covered for any other sleep disorders (central sleep apnea, periodic limb movement disorder, insomnia, parasomnias, circadian rhythm disorders or narcolepsy) or for screening asymptomatic persons.

Physician and Technician Requirements for Sleep Studies and Polysomnography Testing:

- **The physician performing the service must meet one of the following:**
 - be a diplomate of the American Board of Sleep Medicine (ABSM);**OR**

- has a Sleep Certification issued by **ONE** of the following Boards:
 American Board of Internal Medicine (ABIM),
 American Board of Family Medicine (ABFM),
 American Board of Pediatrics (ABP),
 American Board of Psychiatry and Neurology (ABPN),
 American Board of Otolaryngology (ABOto),
 American Osteopathic Board of Neurology and Psychiatry (AOBNP),
 American Osteopathic Board of Family Medicine, (AOBFP)
 American Osteopathic Board of Internal Medicine, (AOBIM)
 American Osteopathic Board of Ophthalmology and Otorhinolaryngology (AOBOO);
OR
- be an active physician staff member of a credentialed sleep center or laboratory that have active physician staff members meeting the criteria above in **a** or **b**.

- **Technician Credentials**

The technician performing the service must meet one of the following:

- American Board of Sleep Medicine (ABSM),
 Registered Sleep Technologist (RST);
- Board of Registered Polysomnographic Technologists (BRPT),
 Registered Polysomnographic Technologist (RPSGT);
- National Board for Respiratory Care (NBRC)
 Certified Pulmonary Function Technologist (CPFT)
 Registered Pulmonary Function Technologist (RPFT)
 Certified Respiratory Therapist (CRT)
 Registered Respiratory Therapist (RRT)

Sleep Center or Laboratory Credentials (this is any site or place of service other than patient's home where sleep studies or recordings are performed)

- The sleep facility credentials must be from the American Academy of Sleep Medicine (AASM), inpatient or outpatient; **OR**
- The Joint Commission (formerly the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) sleep specific credentials for Ambulatory care sleep centers; **OR**
- Accreditation Commission for Health Care (ACHC)
- All centers billing sleep studies must maintain proper certification documentation as defined above.
- The sleep clinic must be affiliated with a hospital or be under the direction and control of a physician (MD/DO), even though the diagnostic test may be performed in the absence of direct physician supervision. This information must be documented and available upon request.
- Sleep disorder clinics may at times render therapeutic as well as diagnostic services. CMS Publication 100-02, *Medicare Benefit Policy Manual*, Chapter 15, Section 70, D. Coverage of Therapeutic Services

Non-covered Services

- **Polysomnography for Chronic Insomnia Is Not Covered.**
 The use of polysomnography for diagnosis of patients with chronic insomnia is not covered

under Medicare because it is not reasonable and necessary under §1862(a)(1)(A) of the Act.

- **Actigraphy Testing:**

Actigraphy measures movement of a limb.

It can be measured as part of a sleep test but will not be paid for separately.

- **Polysomnography or a MSLT is not covered in the following situations:**

- for the diagnosis of patients with chronic insomnia;
- to preoperatively evaluate a patient undergoing a laser assisted uvulopalatopharyngoplasty without clinical evidence that obstructive sleep apnea is suspected;
- to diagnose chronic lung disease (Nocturnal hypoxemia in patients with chronic, obstructive, restrictive, or reactive lung disease is usually adequately evaluated by oximetry. However, if the patient's symptoms suggest a diagnosis of obstructive sleep apnea, polysomnography is considered medically necessary);
- in cases where seizure disorders have not been ruled out;
- in cases of typical, uncomplicated, and non-injurious parasomnias when the diagnosis is clearly delineated;
- for patients with epilepsy who have no specific complaints consistent with a sleep disorder;
- for patients with symptoms suggestive of the periodic limb movement disorder or restless leg syndrome unless symptoms are suspected to be related to a covered indication;
- for the diagnosis of insomnia related to depression;
- for the diagnosis of circadian rhythm sleep disorders (i.e., rapid time-zone change [jet lag], shift-work sleep disorder, delayed sleep phase syndrome, advanced sleep phase syndrome, and non-24-hour sleep wake disorder).

(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicaid Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)

Related Policies

- Actigraphy
- Home Cardiorespiratory Monitoring - Pediatrics
- Obstructive Sleep Apnea and Snoring - Surgical Treatment
- Obstructive Sleep Apnea - Non-surgical Treatment

References

1. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart,

- Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). *Circulation*. Sep 2 2008;118(10):1080-1111. PMID 18725495
2. Kushida CA, Littner MR, Morgenthaler T, et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. *Sleep*. Apr 1 2005;28(4):499-521. PMID 16171294
3. Crook S, Sievi NA, Bloch KE, et al. Minimum important difference of the Epworth Sleepiness Scale in obstructive sleep apnoea: estimation from three randomised controlled trials. *Thorax*. Apr 2019; 74(4): 390-396. PMID 30100576
4. Balk EM, Moorthy D, Obadan NO, et al. Diagnosis and Treatment of Obstructive Sleep Apnea in Adults. Comparative Effectiveness Review No. 32 (Prepared by Tufts Evidence-based Practice Center under Contract No. 290-2007-100551) AHRQ Publication No. 11-EHC052-EF. Rockville MD: Agency for Healthcare Research and Quality Jul 2011.
5. Corral J, Sanchez-Quiroga MA, Carmona-Bernal C, et al. Conventional Polysomnography Is Not Necessary for the Management of Most Individuals with Suspected Obstructive Sleep Apnea. Noninferiority, Randomized Controlled Trial. *Am J Respir Crit Care Med*. Nov 1 2017;196(9):1181-1190. PMID 28636405
6. Mulgrew AT, Fox N, Ayas NT, et al. Diagnosis and initial management of obstructive sleep apnea without polysomnography: a randomized validation study. *Ann Intern Med*. Feb 6 2007;146(3):157-166. PMID 17283346
7. Senn O, Brack T, Russi EW, et al. A continuous positive airway pressure trial as a novel approach to the diagnosis of the obstructive sleep apnea syndrome. *Chest*. Jan 2006;129(1):67-75. PMID 16424414
8. Berry RB, Hill G, Thompson L, et al. Portable monitoring and auto titration versus polysomnography for the diagnosis and treatment of sleep apnea. *Sleep*. Oct 1 2008;31(10):1423-1431. PMID 18853940
9. Ayappa I, Norman RG, Seelall V, et al. Validation of a self-applied unattended monitor for sleep disordered breathing. *J Clin Sleep Med*. Feb 15 2008;4(1):26-37. PMID 18350959
10. Hilmisson H, Berman S, Magnusdottir S. Sleep apnea diagnosis in children using software-generated apnea-hypopnea index (AHI) derived from data recorded with a single photoplethysmogram sensor (PPG): Results from the Childhood Adenotonsillectomy Study (CHAT) based on cardiopulmonary coupling analysis. *Sleep Breath*. Mar 28 2020. PMID 32222900
11. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine Clinical Practice Guideline. *J Clin Sleep Med*. Mar 15 2017;13(3):479-504. PMID 28162150
12. Caples SM, Anderson WM, Calero K, et al. Use of polysomnography and home sleep apnea tests for the longitudinal management of obstructive sleep apnea in adults: an American Academy of Sleep Medicine clinical guidance statement. *J Clin Sleep Med*. Jun 01 2021; 17(6): 1287-1293. PMID 33704050
13. Epstein LJ, Kristo D, Strollo PJ, Jr., et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. *J Clin Sleep Med*. Jun 15 2009;5(3):263-276. PMID 19960649
14. Section on Pediatric Pulmonology - Subcommittee on Obstructive Sleep Apnea Syndrome. Clinical practice guideline: diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics*. Apr 2002;109(4):704-712. PMID 11927718
15. Marcus CL, Brooks LJ, Draper KA, et al. Diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics*. Sep 2012; 130(3): 576-84. PMID 22926173

16. ASMBS Clinical Issues Committee. Peri-operative management of obstructive sleep apnea. Surg Obes Relat Dis. May-Jun 2012;8(3): e27-32. PMID 22503595
17. Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. Jul 20 2021; 144(3): e56-e67. PMID 34148375
18. Mangione CM, Barry MJ, Nicholson WK, et al. Screening for Obstructive Sleep Apnea in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. Nov 15 2022; 328(19): 1945-1950. PMID 36378202
19. Centers for Medicare & Medicaid Services (CMS), Medicare Coverage Database. National Coverage Determination (NCD) for Sleep Testing for Obstructive Sleep Apnea (OSA). Manual Section Number 240.4.1, original date 3/3/09, implementation date 8/10/09.
20. Wisconsin Physicians Service Insurance Corporation, Local Coverage Determination (LCD): Polysomnography and Other Sleep Studies (L36839), original effective date 2/16/17, revision effective date 07/27/2023.

The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through July 2026, the date the research was completed.

Joint BCBSM/BCN Medical Policy History

Policy Effective Date	BCBSM Signature Date	BCN Signature Date	Comments
7/10/02	7/10/02	7/10/02	Joint policy established
2/27/03	2/27/03	3/4/03	Criteria updated
4/11/05	4/11/05	4/11/05	Routine review
11/15/05	11/15/05	11/15/05	Code update
7/1/07	6/24/07	6/24/07	Updated policy
1/1/09	10/13/08	10/13/08	Routine maintenance, added home sleep test codes, title change
9/1/09	6/16/09	6/16/09	Code Updates
5/1/10	2/16/10	2/16/10	Code update – 0203T and 0204T added to policy. Updated description, rationale, criteria and references. Policy title changed to “Sleep Disorders, Diagnosis and Medical Management”. Previous title, “Obstructive Sleep Apnea (OSA) Diagnosis and Management”.
5/1/11	2/15/11	3/3/11	Routine maintenance; code update – deleted CPT codes 0203T and 0204T; added CPT codes 95800 and 95801
7/1/13	4/16/13	4/22/13	Routine maintenance, Code updates
8/1/16	4/19/16	5/23/16	• Routine maintenance • Updated all policy sections • Added negative oral pressure therapy – replacing JUMP policy “Negative Oral Pressure Therapy for the Treatment of OSA” • Moved codes 95801, E0485 & G0400 from established to investigational ○ HST with type IV portable monitor with 3 channels not covered ○ Prefabricated intraoral appliances not covered

			• Removed divergence from BCBSA – now aligned
7/1/17	4/18/17	4/18/17	• Routine maintenance • Description, rationale, Medicare information and references updated
7/1/18	4/17/18	4/17/18	• Routine maintenance • Description/rationale added for nasal EPAP and oral pressure therapy. E/I indications added.
1/1/19	10/16/18	10/16/18	• Routine maintenance • Accreditation language added; responses to AASM input added.
1/1/20	10/15/19		• Routine maintenance • Minimum of 3 channels for testing; updated MPS, inclusions and exclusions • Non-invasive ear and pulse oximeter added to policy (E/I for diagnosis) • Lunoa SPT system (E/I for treatment) • Addition of unexplained nocturia as symptoms • Medicare section updated
1/1/21	10/20/20		Routine maintenance Added Ref 3,10,33
3/1/21	1/5/21		Incorporated IMP “Management of Obstructive Sleep Apnea Syndrome with Oral Appliances”
7/1/21	4/20/21		Exclusions to home sleep studies were updated based upon request from BCN team. They are requesting our policy be more aligned with AIM criteria. Under exclusions for home sleep testing added the below: Added parameters for CHF and COPD Added criterion of inability of individual to apply the home sleep testing equipment Requesting additional exclusions: oxygen dependence

			Requesting additional exclusions: nocturnal seizures Requesting additional exclusions: Congestive heart failure with a history of ventricular fibrillation or sustained ventricular tachycardia in an individual who does not have an implanted defibrillator
7/1/22	4/19/22		• Revised the definition of hypopnea to “at least 3% or 4% arterial oxygen saturation” in Table 1 in order to reflect both AASM and Medicare requirements. • 3/3/22 Request from BCN team to add additional criteria exclusion under home sleep study as these are contraindicated for a Home Sleep Test. ○ History of seizures with use of anticonvulsants ○ Cardiac conditions ○ Restless leg syndrome
7/1/23	4/26/23		• 4/18/23 Followed BCBSA – Sleep Disorders – Diagnosis and Medical Management was split. This JUMP policy is now called Diagnosis of Obstructive Sleep Apnea Syndrome. Information regarding treatment of OSA was moved to the new Medical Management of Obstructive Sleep Apnea Syndrome policy now called Medical Management of Obstructive Sleep Apnea Syndrome (Oral Appliances and Novel Therapies). • Moved codes E0486, E1399, A7047, E0485, K1028, and K1029 to the new Medical Management of Obstructive Sleep Apnea Syndrome Policy. • Added under Inclusion under unattended and attended home sleep study: History of stroke (more than 30 days previously), transient ischemic attack, coronary artery disease, or sustained supraventricular tachycardic or

			bradycardic arrhythmias inpatients who meet ONE of 6 criteria listed above • Removed under exclusions under unattended home sleep apnea test: History of Stroke. Added under exclusions under unattended home sleep apnea test: Idiopathic hypersomnia • Added under Inclusions children younger than 18 years of age: The initial study was inadequate, equivocal or non-diagnostic and the child's parents or caregiver report that the breathing patterns observed at home were different from those during testing. • Added codes 94762 and E0445 from policy Noninvasive Ear or Pulse Oximetry (replaced) as E/I. The topic was incorporated into this policy on 1/1/2020 but codes were not included. Rec'd inquiry from BCN CRC regarding this issue. • Minor editorial refinements – updated patients to individuals. • References added. • Policy statements unchanged. • Vendor: Caelon for BCBSM/internal team for BCN • Post JUMP changes: ○ Policy title changed from Diagnosis of OSA Syndrome to Diagnosis of Sleep Disorders ○ This JUMP policy will not follow Caelon's classification of a child is 18 and younger but will maintain a child is younger than 18. ○ Policy Guidelines section moved to under Description/Background section. ○ Updated the below under Description/Background section under Significant Weight Change from 20% to 10% of
--	--	--	---

			body weight and removed 20kg to be in alignment with Carelon. ○ The purpose/intent of these updates are to align with Carelon and be consistent with our current JUP policy. ○ Under Exclusions/Contraindications to HSAT: dated Periodic limb disorder during sleep to Periodic limb movement disorder (PLMD) when one of the following are present: pregnancy, renal failure, iron deficiency anemia, peripheral neuropathy, use of antidepressant or antipsychotic medications, or continued hypersomnia and clinical symptoms of PLMD after sleep disordered breathing is ruled out by home sleep apnea testing to be in alignment with Carelon. ○ Under Exclusions/Contraindications to HSAT: Removed the below per JUMP committee recommendation: ▪ History of seizures with use of anticonvulsants ▪ Cardiac conditions ▪ Restless leg syndrome ○ Under INITIAL ATTENDED (SUPERVISED) SLEEP STUDY PERFORMED IN A SLEEP LAB clarified section with Adults with suspected OSA. Added Adults with suspected sleep disorders other than OSA: ● An in-lab supervised sleep study may be considered when there is suspicion of ANY of the following: ○ Central sleep apnea ○ Narcolepsy ○ Nocturnal seizures ○ Parasomnia ○ Idiopathic hypersomnia
--	--	--	--

			○ Periodic limb movement disorder (PLMD)—to support a suspicion of PLMD in this context, ONE of the following must be documented: pregnancy, renal failure, iron deficiency anemia, peripheral neuropathy, use of antidepressant or antipsychotic medications, or continued hypersomnia and clinical symptoms of PLMD after sleep disordered breathing is ruled out by home sleep apnea testing ○ Nocturnal desaturation (due to severe COPD or certain restrictive thoracic disorders) ○ Any of the following conditions (right heart failure, polycythemia, cardiac arrhythmias during sleep, or pulmonary hypertension) when the etiology is unclear ● Under REPEATED (ATTENDED) (SUPERVISED) SLEEP STUDY PERFORMED IN A SLEEP LAB: separated adults (18 years of age or older) and added the below children (younger than 18 years of age): ○ Initial PSG is negative and a clinical suspicion of OSA remains ○ Initial study was inadequate, equivocal or non-diagnostic and the child's parents or caregiver report that the breathing patterns observed at home were different from those during testing. ○ A patient with established OSA continues to exhibit persistent snoring or other symptoms of sleep disordered breathing despite PAP adherence as defined by CMS criteria(use of PAP for at least 4 hours per
--	--	--	--

			night on 70% of nights during a consecutive 30-day period) ○ The patient has undergone adenotonsillectomy more than 8 weeks previously for management of established OSA ○ To reevaluate the diagnosis of OSA and need for continued PAP if there is significant weight loss (defined as 10% of body weight) since the most recent sleep study ○ To initiate or titrate CPAP or BPAP in a patient whose diagnostic study confirms that the patient is a candidate for positive airway pressure therapy and split-night study has not been performed or was inadequate: ▪ In pediatric individuals, an AHI greater than 1.5 is considered abnormal, and an AHI of 10 or more may be considered severe. ○ The initial sleep study has led to a diagnosis other than OSA and the repeat study is requested because of a change in clinical status or to assess efficacy after a change in therapy (ky)
1/1/24	10/17/23		• This policy is coming back to JUMP to change 95801 from E/I to Established. This will be in alignment with Carelton and our work with the project. This policy will go back to its original date for review in April of 2024. • Vendor: Carelton for BCBSM/internal team for BCN. (ky)
7/1/24	4/16/24		• Routine maintenance • References updated • Vendor: Carelton (ky)
1/1/25	10/15/24		• Routine maintenance • This policy is coming early for review and to update language to clarify that our intent aligns with Carelton. This policy will continue to

			come to October JUMP moving forward. • Updated Inclusions and Exclusions and MPS section language to clarify that our intent aligns with Carelon. • Vendor: Carelon Sleep Disorder Management 2024-10-20. (ky) Post JUMP: Per JUMP committee discussion removed the below under Repeat attended (supervised) sleep study performed in a sleep lab under both Individuals (18 years of age or older and younger than 18 years of age): • Initial PSG is negative and a clinical suspicion of OSA remains (ky)
7/1/25	4/15/25		• Minor Edits: Added idiopathic hypersomnia to the below statement under the MPS. • Multiple sleep latency testing (MSLT) and maintenance of wakefulness testing (MWT) have been established. They may be useful tools in diagnosing narcolepsy or idiopathic hypersomnia. • This policy will continue to come to October, 2025 JUMP for its annual review to be closer in alignment with BCBSA's update of their policy of July, 2025. • Vendor: Carelon (ky)
11/1/25	8/19/25		• Clarification of inclusion criteria for Initial Attended Sleep Study in a Laboratory, 18 yrs and older • New policy format • Vendor: Carelon (ls)
1/1/26	10/21/25		• Routine maintenance (slp) • Vendor: Carelon • Moved "conditions that may suggest OSA" from "disorders other than OSA" to criteria for in home and in lab inclusions. • CSA bullet under in lab "suspected disorders other than OSA" clarified

			• 18 years of age was removed from contraindications for the use of APAP • Under in-lab sleep tests ○ Parasomnia was clarified that it is likely to result in harm to the individual or others ○ The periodic limb movement bullet was expanded to include insomnia
11/1/26	8/18/26		• Review requested outside of cycle for updates to MPS, Inclusions, and Exclusions for clarity (rh/mk)

Next Review Date: 4th Qtr, 2027

Pre-Consolidation Medical Policy History

Original Policy Date	Comments
BCN: 6/1/97	Revised: 6/28/01
BCBSM: 1/1/97	Revised: N/A

BLUE CARE NETWORK BENEFIT COVERAGE
POLICY: DIAGNOSIS OF SLEEP DISORDERS

I. Coverage Determination:

Commercial HMO (includes Self-Funded groups unless otherwise specified)	Covered, policy criteria apply.
BCNA (Medicare Advantage)	See Government Regulations section.
BCN65 (Medicare Complementary)	Coinsurance covered if primary Medicare covers the service.

II. Administrative Guidelines:

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee of coverage.